Beta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $23.20.

A number of equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday. UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. TD Cowen began coverage on shares of Beta Bionics in a research note on Monday, January 26th. They issued a “hold” rating and a $17.00 target price on the stock. The Goldman Sachs Group restated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research report on Thursday, January 15th. Finally, Robert W. Baird cut their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th.

Insiders Place Their Bets

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the sale, the insider directly owned 82,952 shares in the company, valued at $2,456,208.72. This represents a 8.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 34,705 shares of company stock worth $945,653 in the last three months.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently bought and sold shares of BBNX. Essex Investment Management Co. LLC purchased a new stake in Beta Bionics in the third quarter valued at $4,423,000. Pura Vida Investments LLC lifted its stake in shares of Beta Bionics by 11,150.0% in the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after purchasing an additional 278,750 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in shares of Beta Bionics during the 2nd quarter worth $13,817,000. Farallon Capital Management LLC increased its position in shares of Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after purchasing an additional 110,000 shares during the last quarter. Finally, First Eagle Investment Management LLC acquired a new stake in shares of Beta Bionics during the 3rd quarter worth about $4,634,000.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $9.86 on Tuesday. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The stock’s fifty day moving average is $12.88 and its two-hundred day moving average is $21.26. The firm has a market capitalization of $437.59 million, a P/E ratio of -5.06 and a beta of 5.59.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.